Anteris talks market superiority of its biomimetic TAVR valve 

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the company’s early feasibility study (EFS) to evaluate DurAVR™ THV. This unique device represents a new class of biomimetic valve and stands as the world's only balloon-expandable, single-piece transcatheter aortic valve. The study aims to assess the safety and feasibility of DurAVR™ THV in treating 15 patients suffering from symptomatic, severe native aortic stenosis, and is critical to obtaining US Food and Drug Administration clearance.
#ProactiveAustralia #ASX #AVR #biomimeticvalve
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews